Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient

Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient

BackgroundTrastuzumab plus chemotherapy remains the standard first-line treatment strategy for HER2-positive gastric cancer (GC). Trastuzumab resistance, on the other hand, remains a significant issue. There are a few effective anti-HER2 agents for patients who develop resistance to trastuzumab.Case...

Full description

Bibliographic Details
Main Authors: Junyi Wu, Lei Li, Jun Qin, Zhengqing Yan, Shiqing Chen, Tao Jin, Junming Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
gastric cancer
HER2
trastuzumab
resistance
pyrotinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.780577/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.780577/full

Similar Items